Gastrointestinal diseases: IBS
ECS and cannabinoids modulate the GIT through CB1 and CB2 receptors and via other pathways. In the Gastrointestinal system (GIT), it modulates peristalsis (intestinal movement), secretions, inflammation and pain. It also modulates appetite and energy utilization (metabolism).
ECS and cannabinoids modulate the GIT through CB1 and CB2 receptors and via other pathways. In the Gastrointestinal system (GIT), it modulates peristalsis (intestinal movement), secretions, inflammation and pain. It also modulates appetite and energy utilization (metabolism).
Irritable bowel Syndrome (IBS) comes under clinical endocannabinoid deficiency syndrome and it has been quite extensively studied.
Another major area of interest is chemotherapy induced nausea and vomiting and THC via CB1 receptors modulates this. Adjuvant CBD along with chemotherapy reduces the adverse events and thereby making the therapy more tolerable.
Reference:
Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy. Samiksha Pandey. Complement Ther Med. 2020 Jan;48:102242. doi: 10.1016/j.ctim.2019.102242. Epub 2019 Nov 13.
Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment. Viola Brugnatelli et al. Front Neurosci. 2020; 14: 371. Published online 2020 Apr 21. doi: 10.3389/fnins.2020.00371
Cannabidiol in inflammatory bowel diseases: a brief overview. Giuseppe Esposito et al. Phytother Res. 2013 May;27(5):633-6. doi: 10.1002/ptr.4781. Epub 2012 Jul 20.